FANSS study: low-dose CT screening feasible, valuable for lung cancer screening for Asian non-smoking women
Supports expansion of guidelines to include high-risk populations
Presenter: @elaineshummd.bsky.social
Discussant: David R. Baldwin, MD
ascopost.com/news/october...
Challenges in Delivering Financial Assistance After Positive Financial Toxicity Screens - Fumiko Ladd Chino
@fumikochino.bsky.social @chaewonhwangmd.bsky.social @jbudhu.bsky.social @bthomphd.bsky.social
oncodaily.com/voices/fumik...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedOnc #MedNews
Additionally, there was no correlation between level of #financialtoxicity and the type of planned #radiationtherapy, CyberKnife SBRT, or hypofractionated/conventional EBRT. Important to note that this was baseline survey prior to start of RT! Longitudinal data is being collected
Despite our prostate cancer patients being more likely to report low #financialtoxicity, those with high FT were still more likely to engage in cost-coping mechanisms like delaying or avoiding medical care and reducing spending on leisure, which can negatively impact outcomes and QoL
Excited to share our findings regarding #financialtoxicity of our patients with prostate cancer presenting for #radiationtherapy @bidmc-cancercenter.bsky.social @bidmcreseach.bsky.social ! And excited to learn more about delivery of quality care and barriers to cancer care at #ASCOQLTY25!
#ASTRO25 ! Thank you for the opportunity to present our work on #financialtoxicity in patients undergoing radiation treatment, specifically on baseline FT and cost-coping mechanisms. Stay tuned for #ASCOQLTY25 for subanalysis on our prostate cancer patient cohort! #radonc
Abstract titles for #ASCOQLTY25 are now live! Get a first look at the solution-oriented cancer research that will be presented at the symposium: asco.org/qcs-abstracts
If you haven’t yet confirmed your attendance, registration is still open: brnw.ch/21wVpzR
More news from #ASCO25 Plenary! MATTERHORN results: Perioperative durvalumab/FLOT shows superior EFS over placebo/FLOT in early-stage, resectable G/GEJ cancer: brnw.ch/21wT4R8
#ASCODailyNews #GICSM
Day 3 of #ASCO25 ! Honored to be presenting on how social determinants of health affect immunotherapy use in Stage III NSCLC patients after definitive chemoradiation @ascocancer.bsky.social @bidmcreseach.bsky.social @bidmc-cancercenter.bsky.social #TuftsMedicalCenter
Day 2 of #ASCO25! Exciting new frontiers in harnessing power of AI to better cancer care! As Dr. Robin Zon, President of @ascocancer.bsky.social, & Ms. Ruth Porat, President & CIO of Google and Alphabet, mentioned, AI is augmenting human capabilities, and it's about using it as an agent for change
@cliffordhudis.bsky.social at #ASCO25: ~40% cut to NCI budget in Admin's '26 proposal. We are in a tragic paradox: remarkable science & historic cuts to resources needed to turn these opps into hope for millions of pts. Our advocacy, is more important than ever ➡️ brnw.ch/21wT3U4
Thrilled to be at #ASCO25 ! Excited to witness and be a part of the forefront of cancer research! And honored to present research @ascocancer.bsky.social
The most clinically relevant science in oncology will be presented at #ASCO25, and you can now view the full 5,000 abstracts & their presentation date, time & location info: brnw.ch/21wSRrH
Incredible findings of Phase II study where px with stage I, II, or III dMMR solid tumors that were amenable to curative-intent surgery were treated with neoaduvant dostarlimab for 6 months:
➡️ recurrence-free survival at 2 years was 92%
#AACR25 #Oncology #research
www.nejm.org/doi/full/10....
📣 Phase III KEYNOTE-689 trial: Addition of perioperative Pembrolizumab to standard of care tx for locally advanced HNSCC significantly improved event free survival and major pathologic response. Presented
@ #AACR 2025 meeting: www.aacr.org/about-the-aa...
#Oncology #research #radonc
Helpful guide to responding to reviewers, when submitting research to journals: www.sciencedirect.com/science/arti...
#meded #oncology #research #radonc
Excited to be presenting our research #ASCO meeting this year! Can't wait to share our findings on patterns of immunotherapy use in different groups of stage 3 NSCLC patients who were treated definitively with chemoRT:
meetings.asco.org/abstracts-pr...
@bidmcreseach.bsky.social
#TuftsMedicine
📣 Big shoutout to our faculty at #TuftsMedicine & @bidmc-cancercenter.bsky.social radiation oncology residency, Dr. Jang and Dr. Huber, for being speaker and moderator at this year's @astro-org.bsky.social Annual RefresherCourse! Thank you for all that you do for us and for the #radonc community!
"Deintensification of chemoradiation treatments for HPV-associated oropharyngeal cancers is of very high interest to patients and researchers, but our study makes clear that these approaches should remain experimental.”
— SUE YOM, MD, PhD, FASTRO. ascopost.com/news/april-2...
@ascopost.bsky.social
We had a record number of abstracts submitted for #ACRO2025! 👏 Impressive work by all our residents who presented at #ACROinVegas! See all the photos here: www.facebook.com/media/set?va...
